Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Resveratrol

Drug · 3 studies in the Atlas

Plant polyphenol popularized as a sirtuin activator and 'calorie-restriction mimetic'; failed to extend lifespan in ITP mouse studies and showed no metabolic benefit in a human RCT.

Evidence at a glance

EvidenceWhat it meansStudies
H Human study1
A Animal model2

Studies

YearEvidenceStudy
2013 H High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition POU2013 4 weeks of high-dose resveratrol had no effect on insulin sensitivity, blood pressure, or body composition - directly contradicting the promising rodent data that drove the original hype.
2012 A Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice STR2012 None of five popular longevity compounds had a statistically significant effect on lifespan. The paper explicitly states the ITP's mission is to publish all results, positive or negative - the exact registry model this Atlas should emulate.
2011 A Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice MIL2011 In the same experimental design that showed rapamycin extended median lifespan by 10-18%, neither resveratrol nor simvastatin had any significant effect on survival - a direct head-to-head negative control run at the same time, in the same mice.

Related entities

Longevity 2CurcuminMCT oilRapamycin 1Oxaloacetic acidmTOR 1SimvastatinGreen tea extractInsulin resistance 1